Angiocentric glioma: report of clinico-pathologic and genetic findings in 8 cases

Am J Surg Pathol. 2007 Nov;31(11):1709-18. doi: 10.1097/PAS.0b013e31804a7ebb.

Abstract

Angiocentric glioma has recently been described as a novel epilepsy associated tumor with distinct clinico-pathologic features. We report the clinical and pathologic findings in 8 additional cases of this rare tumor type and extend its characterization by genomic profiling. Almost all patients had a history of long-standing drug-resistant epilepsy. Cortico-subcortical tumors were located in the temporal and parietal lobes. Seizures began at 3 to 14 years of age and surgery was performed at 6 to 70 years. Histologically, the tumors were characterized by diffuse growth and prominent perivascular tumor cell arrangements with features of astrocytic/ependymal differentiation, but lacking neoplastic neuronal features. Necrosis and vascular proliferation were not observed and mitoses were sparse or absent. MIB-1 proliferation indices ranged from <1% to 5%. Immunohistochemically, all cases stained positively for glial fibrillary acidic protein, vimentin, protein S100B, variably for podoplanin, and showed epithelial membrane antigen-positive cytoplasmic dots. Electron microscopy showed ependymal characteristics in 2 of 3 cases investigated. An analysis of genomic imbalances by chromosomal comparative genomic hybridization revealed loss of chromosomal bands 6q24 to q25 as the only alteration in 1 of 8 cases. In 1 of 3 cases, a high-resolution screen by array-comparative genomic hybridization identified a copy number gain of 2 adjacent clones from chromosomal band 11p11.2 containing the protein-tyrosine phosphatase receptor type J (PTPRJ) gene. All patients are seizure free and without evidence of tumor recurrence at follow-up times ranging from 1/2 to 6.9 years. Our findings support 2 previous reports proposing that angiocentric glioma is a novel glial tumor entity of low-grade malignancy.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Astrocytes / pathology
  • Brain Neoplasms / chemistry
  • Brain Neoplasms / complications
  • Brain Neoplasms / genetics*
  • Brain Neoplasms / surgery
  • Brain Neoplasms / ultrastructure*
  • Cell Differentiation
  • Cell Proliferation
  • Child
  • Child, Preschool
  • Chromosome Deletion
  • Chromosomes, Human, Pair 11
  • Chromosomes, Human, Pair 6
  • Ependyma / pathology
  • Epilepsy / genetics*
  • Epilepsy / pathology
  • Epilepsy / prevention & control
  • Europe
  • Female
  • Follow-Up Studies
  • Gene Dosage
  • Gene Expression Profiling / methods
  • Gene Expression Regulation, Neoplastic*
  • Glial Fibrillary Acidic Protein / analysis
  • Glioma / chemistry
  • Glioma / complications
  • Glioma / genetics*
  • Glioma / surgery
  • Glioma / ultrastructure*
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Membrane Glycoproteins / analysis
  • Middle Aged
  • Mucin-1 / analysis
  • Nerve Growth Factors / analysis
  • Nucleic Acid Hybridization
  • Oligonucleotide Array Sequence Analysis
  • Receptor-Like Protein Tyrosine Phosphatases, Class 3 / genetics
  • S100 Calcium Binding Protein beta Subunit
  • S100 Proteins / analysis
  • Time Factors
  • Treatment Outcome
  • Vimentin / analysis

Substances

  • Glial Fibrillary Acidic Protein
  • Membrane Glycoproteins
  • Mucin-1
  • Nerve Growth Factors
  • PDPN protein, human
  • S100 Calcium Binding Protein beta Subunit
  • S100 Proteins
  • S100B protein, human
  • Vimentin
  • PTPRJ protein, human
  • Receptor-Like Protein Tyrosine Phosphatases, Class 3